Grundläggande statistik
| CIK | 716778 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to SPO Global Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| June 14, 2017 |
spom1a.htm An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the offering statement filed with the Commission is qualified. This Preliminary |
|
| June 14, 2017 |
An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| June 13, 2017 |
spomcorresp.htm SPO GLOBAL, INC. June 13, 2017 United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Gabriel Eckstein VIA: EDGAR Re: SPO Global Inc. Offering Statement on Form 1-A Filed May 26, 2017 File No. 024-10663 Dear Ms. Maryse Mill-Apeteng: Further to our receipt of confirmation from your office that all comments on |
|
| May 26, 2017 |
1-A/A LIVE 0000716778 XXXXXXXX 024-10663 SPO Global Inc DE 2014 0000716778 5045 25-1411971 7 0 800 W Cummings Park Suite 2000 Woburn MA 01801 407-517-4854 William Eilers Other 21568. |
|
| May 26, 2017 |
An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| May 8, 2017 |
An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| May 8, 2017 |
1-A/A LIVE 0000716778 XXXXXXXX 024-10663 SPO Global Inc DE 2014 0000716778 5045 25-1411971 7 0 800 W Cummings Park Suite 2000 Woburn MA 01801 407-517-4854 William Eilers Other 21568. |
|
| April 28, 2017 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: March 31, 2018 Estimated average burden hours per response. 1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT |
|
| April 10, 2017 |
spomcorresp.htm SPO GLOBAL, INC. April 10, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attn: Gabriel Eckstein VIA: EDGAR Re: SPO Global, Inc. Amendment No. 1 to Offering Statement on Form 1-A Filed January 24, 2017 File No. 024-10663 Ladies and Gentlemen: SPO Global, Inc. (the ?Company?), is filing with |
|
| April 6, 2017 |
spom1a.htm An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the offering statement filed with the Commission is qualified. This Preliminary |
|
| January 24, 2017 |
Licensing Agreement Between SPO Global, Inc. and SPO Medical Equipment, Inc. EXHIBIT 6.1 This MASTER LICENSE AGREEMENT is made as of December 22, 2015, BETWEEN SPO Global Inc., a Delaware company, and its wholly owned subsidiary SPO Medical Equipment Ltd., an Israeli company (jointly the “Licensor”); ‘and’ Michael Braunold (the “Licensee”). WHEREAS The Licensor is the exclusive legal owner of all rights, title and interest in the IP and SPO Technology as defined below, and |
|
| January 24, 2017 |
Opinion of Eilers Law Group, P.A. regarding legality of the securities covered in this Offering spomex121.htm EXHIBIT 12.1 1000 Fifth Street PO Box 5025 Suite 200 ? P2 Asheville, NC 28813 Miami Beach, FL 33139 Phone: 786.273.9152 www.eilerslawgroup.com January 6, 2017 Gentlemen: We are acting as counsel to SPO Global, Inc. (the ?Company?) in connection with the preparation and filing with the Securities and Exchange Commission, under the Securities Act of 1933, as amended, of the Company?s O |
|
| January 24, 2017 |
Certificate of Amendment – Name Change to United Diagnostics, Inc. spomex21.htm EXHIBIT 2.1 AMENDMENT OF CERTIFICATE OF INCORPORATION OF NU-TECH BIO-MED, INC. Nu-Tech Bio-Med, Inc., in order to amend its Amended and Restated Certificate of Incorporation (the "Restated Certificate"), hereby certifies as follows: FIRST: The name of the corporation is NU-TECH BIO-MED, INC. SECOND: The corporation hereby amends its Certificate of Incorporation as follows: 1. Article |
|
| January 24, 2017 |
EX1A-3 HLDRS RTS 8 spomex31.htm CERTIFICATE OF DESIGNATION EXHIBIT 3.1 |
|
| January 24, 2017 |
Securities Purchase Agreement with Blackbridge Capital, LLC spomex11.htm EXHIBIT 1.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 23, 2016 by and between SPO Global Inc., a Delaware corporation, with headquarters located at 800 W Cummings Park, Suite 2000, Woburn, MA O1801 (the "Company"), and Blackbridge Capital Growth Fund, LLC, a Delaware limited liability company, with its address at 450 7th Ave, |
|
| January 24, 2017 |
Certificate of Amendment – Name Change to SPO Medical, Inc. EXHIBIT 2.2 |
|
| January 24, 2017 |
EXHIBIT 2.4 BY-LAWS of SPO Medical Inc. (a Delaware corporation) Article I Offices 1.1 The Board of Directors (the "Board") of the corporation shall fix the location of the principal executive office of the corporation at any place within or outside the State of Delaware. 1.2 The Board may at any time establish branch or subordinate offices at any place or places. Article II Meetings of Stockholde |
|
| January 24, 2017 |
An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| January 24, 2017 |
Certificate of Amendment – Name Change to SPO Global, Inc. spomex23.htm EXHIBIT 2.3 |
|
| January 6, 2017 |
Certificate of Amendment – Name Change to SPO Medical, Inc. EXHIBIT 2.2 |
|
| January 6, 2017 |
Securities Purchase Agreement with Blackbridge Capital, LLC EXHIBIT 1.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of June 23, 2016 by and between SPO Global Inc., a Delaware corporation, with headquarters located at 800 W Cummings Park, Suite 2000, Woburn, MA O1801 (the "Company"), and Blackbridge Capital Growth Fund, LLC, a Delaware limited liability company, with its address at 450 7th Ave, Suite 609, Ne |
|
| January 6, 2017 |
Opinion of Eilers Law Group, P.A. regarding legality of the securities covered in this Offering EXHIBIT 12.1 1000 Fifth Street PO Box 5025 Suite 200 ? P2 Asheville, NC 28813 Miami Beach, FL 33139 Phone: 786.273.9152 www.eilerslawgroup.com January 6, 2017 Gentlemen: We are acting as counsel to SPO Global, Inc. (the ?Company?) in connection with the preparation and filing with the Securities and Exchange Commission, under the Securities Act of 1933, as amended, of the Company?s Offering Statem |
|
| January 6, 2017 |
An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| January 6, 2017 |
Certificate of Amendment – Name Change to United Diagnostics, Inc. EXHIBIT 2.1 AMENDMENT OF CERTIFICATE OF INCORPORATION OF NU-TECH BIO-MED, INC. Nu-Tech Bio-Med, Inc., in order to amend its Amended and Restated Certificate of Incorporation (the "Restated Certificate"), hereby certifies as follows: FIRST: The name of the corporation is NU-TECH BIO-MED, INC. SECOND: The corporation hereby amends its Certificate of Incorporation as follows: 1. Article FIRST of the |
|
| January 6, 2017 |
EXHIBIT 3.1 |
|
| January 6, 2017 |
Certificate of Amendment – Name Change to SPO Global, Inc. EXHIBIT 2.3 |
|
| January 6, 2017 |
Licensing Agreement Between SPO Global, Inc. and SPO Medical Equipment, Inc. EXHIBIT 6.1 This MASTER LICENSE AGREEMENT is made as of December 22, 2015, BETWEEN SPO Global Inc., a Delaware company, and its wholly owned subsidiary SPO Medical Equipment Ltd., an Israeli company (jointly the ?Licensor?); ?and? Michael Braunold (the ?Licensee?). WHEREAS The Licensor is the exclusive legal owner of all rights, title and interest in the IP and SPO Technology as defined below, and |
|
| January 6, 2017 |
BY-LAWS SPO Medical Inc. (a Delaware corporation) Article I EXHIBIT 2.4 BY-LAWS of SPO Medical Inc. (a Delaware corporation) Article I Offices 1.1 The Board of Directors (the "Board") of the corporation shall fix the location of the principal executive office of the corporation at any place within or outside the State of Delaware. 1.2 The Board may at any time establish branch or subordinate offices at any place or places. Article II Meetings of Stockholde |
|
| August 14, 2015 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-11772 SPO Global Inc. (Exact name of registrant as specified in its charter) 3 Gavish |
|
| August 10, 2015 |
SPOM / SPO Global Inc. / KCG AMERICAS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A Under the Securities Exchange Act of 1934 (Amendment 2) SPO Global Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78468T107 (CUSIP Number) July 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| May 14, 2015 |
SPO Global SPO GLOBAL INC., 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2015 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO GLOBA |
|
| April 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 spom-2014123110k.htm SPO GLOBAL INC., 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K MARK ONE: [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2014 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 |
|
| April 1, 2015 |
SPO Global SPO GLOBAL INC., NT 10-K OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. 2.50 FORM 12b-25 SEC FILE NUMBER 0-11772 CUSIP NUMBER NOTIFICATION OF LATE FILING 67019L101 (Check one): [x] Form 10-K [] Form 20-F [] Form 11-K [] Form 10-Q [] Form 10-D [] Form N-SAR [] Form N-CSR For Period Ended: Decemb |
|
| February 6, 2015 |
SPOM / SPO Global Inc. / KCG AMERICAS LLC - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 d867062dsc13ga.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment 1) SPO Global Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78468T107 (CUSIP Number) January 30, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 6, 2015 |
SPOM / SPO Global Inc. / KCG AMERICAS LLC - SCHEDULE 13G Passive Investment SC 13G 1 d867069dsc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Initial Filing) Under the Securities Exchange Act of 1934 SPO Global Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 78468T107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 spom-2014093010q.htm SPO GLOBAL 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2014 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period fr |
|
| August 14, 2014 |
EX-3.1 2 exhibit3-1.htm EXHIBIT-3.1 Exhibit 3.1 1 2 3 |
|
| August 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 spog-2014063010q.htm SPO GLOBAL INC., 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2014 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period |
|
| May 15, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2014 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO GLOBA |
|
| April 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 spom-2013123110k.htm SPO MEDICAL 10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K MARK ONE: [ X ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2013 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 SPO |
|
| April 9, 2014 |
Exhibit 3.1 1 2 3 |
|
| April 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 0-11772 CUSIP Number 67019L101 (Check one) : [x] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2013 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Transition Report on Form 10-Q [ ] Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| January 3, 2014 |
8-K 1 spom-201301038k.htm SPO GLOBAL INC., 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2013 SPO GLOBAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jur |
|
| November 13, 2013 |
Exhibit 3.1 1 2 3 |
|
| November 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE [X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2013 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO G |
|
| September 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Information Statement o Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement SPO MEDICAL INC. (Name of Registrant |
|
| September 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement o Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2)) o Definitive Information Statement SPO MEDICAL INC. (Name of Registrant |
|
| August 30, 2013 |
8-K 1 spom8k-20130830.htm SPO MEDICAL 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2013 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdicti |
|
| August 30, 2013 |
1 CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK OF SPO MEDICAL INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK SPO Medical INC. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the "DGCL"), certifies that, pursuant to authority co |
|
| August 30, 2013 |
SERIES A PREFERRED STOCK PURCHASE AGREEMENT Exhibit 10.1 SERIES A PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES A PREFERRED STOCK PURCHASE AGREEMENT (the “Agreement”), made as of the last date executed below (the “Effective Date”), by and among SPO Medical Inc. a Delaware corporation with a principal address of 3 Gavish Street, Kfar Saba Israel (“the “Company”), and Michael Braunold, an individual with an address of c/o 3 Gavish Steet Kfar |
|
| August 8, 2013 |
EX-4.1 2 exhibit4-1.htm EXHIBIT 4.1 EXHIBIT 4.1 FORM OF WARRANT NEITHER THIS WARRANT NOR THE SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE REPRESENTATIONS AND AGREEMENTS MADE BY THE RECORD HOLDER HEREOF SET FORTH IN THIS WARRANT. SPO M |
|
| August 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 spom-2013063010q.htm SPO MEDICAL 10Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE [ X ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2013 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from |
|
| August 8, 2013 |
FORM OF SUBSCRIPTION AGREEMENT EX-10.1 3 exhibit10-1.htm EXHIBIT 10.1 EXHIBIT 10.1 FORM OF SUBSCRIPTION AGREEMENT SPO Medical Inc. Attention: Michael Braunold, CEO Gentlemen: 1. Subscription. (a) Subject to the terms and conditions of this Agreement the undersigned (the "Purchaser") hereby irrevocably subscribes for and agrees to purchase shares of the common stock, par value $0.01 per share (each a “Share” and collectively, th |
|
| May 16, 2013 |
SPOM / SPO Global Inc. / LE7 Consulting LLC - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. )* SPO Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67019L101 (CUSIP Number) May 8, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] [X] |
|
| May 16, 2013 |
SPOM / SPO Global Inc. / AM145 Holdings LLC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SPO Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67019L101 (CUSIP Number) May 8, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] [X] |
|
| May 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE [ X ] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2013 or [ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MED |
|
| April 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 spom20121231-10q.htm SPO MEDICAL 10K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K MARK ONE: x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL |
|
| April 1, 2013 |
NT 10-K 1 spo-20130401nt10k.htm NT 10K - SPO MEDICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 0-11772 CUSIP Number 67019L101 (Check one) : x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2012 ¨ Transition Report on Form 10-K ¨ Transition Report o |
|
| November 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE S Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2012 or Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL |
|
| August 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2012 or Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. |
|
| May 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 v31311710q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2012 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FI |
|
| April 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K MARK ONE: x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2011 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Name of registrant as specified in it |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 0-11772 CUSIP Number 67019L101 (Check one) : x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR For Period Ended: December 31, 2011 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| December 1, 2011 |
3 Gavish Street POB 2454 Kfar Saba Israel 44254 December 1, 2011 By EDGAR Mr. Eric Atallah Staff Accountant Securities and Exchange Commission Washington, D.C. 20549 Dear Mr. Atallah Re: SPO Medical Inc. (the “Company”) Form 10-K for the year ended December 31, 2010 Filed April 14, 2011 File No. 000-11772 With reference to the comment letter dated October 13, 2011 from the Staff of the Commission |
|
| November 21, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2011 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDIC |
|
| November 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 0-11772 CUSIP Number 67019L101 (Check one) : o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| September 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No.1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No.1) MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2011 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-1 |
|
| August 22, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 v23005910q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2011 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: |
|
| August 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 0-11772 CUSIP Number 67019L101 (Check one) : o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: June 30, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| July 13, 2011 |
EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT Registration Rights Agreement (the ?Agreement?), dated as of July 5, 2011, by and between SPO Medical, Inc., a corporation organized under the laws of Delaware, USA (the ?Company?), and Dutchess Opportunity Fund, II, LP, a Delaware Limited Partnership (the ?Investor?). Whereas, in connection with the Investment Agreement by and between the Company and the |
|
| July 13, 2011 |
EX-10.1 2 v228560ex10-1.htm EXHIBIT 10.1 INVESTMENT AGREEMENT INVESTMENT AGREEMENT (this “AGREEMENT”), dated as of July 5, 2011 by and between SPO Medical, Inc. a Delaware corporation (the “Company”), and Dutchess Opportunity Fund, II, LP, a Delaware Limited Partnership (the “Investor”). WHEREAS, the parties desire that, upon the terms and subject to the conditions contained herein, the Investor s |
|
| July 13, 2011 |
Entry into a Material Definitive Agreement 8-K 1 v2285608k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2011 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (Co |
|
| May 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2011 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL I |
|
| May 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 0-11772 CUSIP Number 67019L101 (Check one) : o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: March 31, 2011 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| April 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K MARK ONE: x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2010 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Name of registrant as specified in it |
|
| April 14, 2011 |
Exhibit 3.1 |
|
| March 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number 0-11772 CUSIP Number 67019L101 (Check one) : x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2010 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| November 15, 2010 |
SPO MEDICAL INC. FORM OF WARRANT EX-4.1 2 v202200ex4-1.htm EXHIBIT 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES A |
|
| November 15, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2010 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDIC |
|
| November 15, 2010 |
FORM OF SUBSCRIPTION AGREEMENT EXHIBIT 10.2 FORM OF SUBSCRIPTION AGREEMENT SPO Medical Inc. 3 Gavish Street POB 2454 Kfar Saba Israel Attn: Michael Braunold, Chief Executive Officer Ladies and Gentlemen: 1. Subscription. The undersigned (the ?Purchaser?), intending to be legally bound, hereby irrevocably agrees to purchase from SPO Medical Inc., a Delaware corporation (the ?Company?), the number of Units (as defined below) of t |
|
| November 15, 2010 |
EX-10.1 3 v202200ex10-1.htm EXHIBIT 10.1 PLACEMENT AGENCY AGREEMENT July 12, 2010 Emerson Equity LLC 155 Bovet Road, Suite 725 San Mateo, CA 94402 Re: SPO Medical Inc. Ladies and Gentlemen: This Placement Agency Agreement (this “Agreement”) sets forth terms upon which Emerson Equity LLC, a registered broker-dealer and a member of the Financial Industry Regulatory Authority (“FINRA”) (together with |
|
| September 22, 2010 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2010 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (Commission File |
|
| August 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (RULE 14C-101) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: o Preliminary Information Statement x Definitive Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) SPO MEDICAL INC. (Name of Registr |
|
| August 19, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (RULE 14C-101) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C (RULE 14C-101) Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement o Definitive Information Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) SPO MEDICAL INC. (Name of Registr |
|
| August 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2010 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL IN |
|
| August 4, 2010 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities 8-K 1 v1924438k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2010 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (C |
|
| July 30, 2010 |
Unregistered Sales of Equity Securities 8-K 1 v1919908k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2010 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (C |
|
| July 12, 2010 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2010 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 2, 2010 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2010 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2010 or ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL I |
|
| April 13, 2010 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2010 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (Commission File |
|
| March 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K MARK ONE: x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2009 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Name of registrant as specified in it |
|
| March 29, 2010 |
TERMINATION & SETTLEMENT AGREEMENT Exhibit 10.18 TERMINATION & SETTLEMENT AGREEMENT TERMINATION & SETTLEMENT AGREEMENT dated and effective as of the 24th day December 2009 by and between SPO Medical Inc. (the ?Company?) and Jeff Feuer (the ?Employee?). WITNESSETH WHEREAS, SPO Medical, Inc. entered into employment agreement with Employee dated July 14 2005 (the "Employment Agreement"); and WHEREAS, the Company has decided to termina |
|
| March 29, 2010 |
TERMINATION & SETTLEMENT AGREEMENT EX-10.17 2 v178570ex10-17.htm Exhibit 10.17 TERMINATION & SETTLEMENT AGREEMENT TERMINATION & SETTLEMENT AGREEMENT dated and effective as of the 24th day December 2009 by and between SPO Medical Equipment Ltd. (the “Company”) and Jeff Feuer (the “Employee”). WITNESSETH WHEREAS, SPO Medical Equipment Ltd. entered into employment agreement with Employee dated May 15 2005, as amended on June 1 2007 (t |
|
| March 29, 2010 |
EX-10.19 4 v178570ex10-19.htm Exhibit 10.19 ALLIANCE & LICENSE AGREEMENT This Alliance & License Agreement (the “Agreement”), effective as of December 1, 2009 (the “Effective Date”), is entered into by and between SPO Medical Equipment Ltd. (the “Company”) and SPO Medical Systems Ltd. (the “Licensee”). RECITALS WHEREAS, the Company develops and manufactures technology for measuring pulse and blood |
|
| February 1, 2010 |
Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets 8-K 1 v1728358k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2010 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) |
|
| December 31, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 24, 2009 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 16, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2009; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDI |
|
| August 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2009; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL I |
|
| May 15, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2009; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL |
|
| May 13, 2009 |
Beit Hapa’amon, Suite 209 20 Hata’as St POB 2454 Kfar Saba Israel 44254 13 May 2009 By EDGAR Mr. |
|
| March 31, 2009 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K MARK ONE: x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2008 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Name of registrant |
|
| November 18, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2008; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDI |
|
| August 14, 2008 |
EX-10.1 2 v122215ex10-1.htm Exhibit 10.1 Mutual Release & Waiver In consideration of 400,000 shares of Common Stock of SPO Medical Inc. being issued to Active Health Care, Inc. and in consideration of the sum of $10 paid by Active Health Care, Inc. to SPO Medical Inc., the receipt and adequacy of which is hereby acknowledged, each of the undersigned (on its behalf and on behalf of each of its affi |
|
| August 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2008; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL I |
|
| May 15, 2008 |
Beit Hapa’amon, Suite 209 20 Hata’as St POB 2454 Kfar Saba Israel 44254 15 May 2008 By EDGAR Mr. |
|
| May 14, 2008 |
SPO MEDICAL INC. SUBSCRIPTION AGREEMENT Name of Offeree EXHIBIT 10.3 SPO MEDICAL INC. SUBSCRIPTION AGREEMENT SPO Medical Inc. Beit Hapa’amon, Suite 209, 20 Hata’as Street, Kfar Saba Israel 44425 Telephone No.: (011-972-9) 764-3570 Telecopier No.: (011-972-9) 764-3571 Attention: Michael Braunold Gentlemen: 1. Subscription. (a) Subject to the terms and conditions of this Agreement the undersigned (the "Purchaser") hereby irrevocably subsc |
|
| May 14, 2008 |
EX-4.1 2 v113877ex4-1.htm EXHIBIT 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAW OR SPO MEDICAL GROUP, |
|
| May 14, 2008 |
FORM OF SECOND AMENDMENT TO AN SPO SUBSCRIPTION AGREEMENT EX-10.2 5 v113877ex10-2.htm EXHIBIT 10.2 FORM OF SECOND AMENDMENT TO AN SPO SUBSCRIPTION AGREEMENT SECOND Amendment to an SPO Subscription Agreement, (the “Subscription Agreement”), between SPO Medical Inc. (the “Company, or SPO”) and the undersigned subscriber (the “Subscriber”) to the Subscription Agreement. Whereas, under the Subscription Agreement entered into in 2005, SPO sold Subscriber cert |
|
| May 14, 2008 |
COMMON STOCK PURCHASE WARRANT Expires _______________, 2011 EXHIBIT 4.2 THE SECURITIES REPRESENTED BY THIS CERTIFICATE (THE ?SECURITIES?) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) OR STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE ACT AND UNDER APPLICABLE STATE SECURITIES LAW OR SPO MEDICAL INC. (THE ?COMPANY?) SHALL HAVE R |
|
| May 14, 2008 |
FORM OF WARRANT EXERCISE & NOTE CONVERSION AGREEMENT EX-10.1 4 v113877ex10-1.htm EXHIBIT 10.1 FORM OF WARRANT EXERCISE & NOTE CONVERSION AGREEMENT This Agreement (the “Agreement”), made as of the 26th day of March 2008 between SPO Medical Inc. (the “Company, or SPO”) and the undersigned subscriber (the “Subscriber”). Whereas SPO and Subscriber entered into a Subscription Agreement dated September 2005, as subsequently amended, whereby SPO sold Subsc |
|
| May 14, 2008 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2008; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Exact na |
|
| March 21, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB MARK ONE: x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Name of Small Business Issuer in its chapter) D |
|
| November 5, 2007 |
EX-10.2 3 v091920ex10-2.htm Exhibit 10.2 FORM OF AGREEMENT WHEREAS under a Subscription Agreement in 2006, SPO Medical Inc. (“SPO”) sold Subscriber (named below) certain SPO securities consisting of (i) a 8% promissory notes with interest and principal repayable at the end of 12 months (the “Note”); and (ii) a two year common stock purchase warrant to purchase 16,250 shares of Common Stock of the |
|
| November 5, 2007 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2007; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Ex |
|
| November 5, 2007 |
Exhibit 10.1 THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (?SUBSCRIPTION AGREEMENT?) RELATES TO AN OFFERING OF SECURITIES IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?1933 ACT?). NONE OF THE SECURITIES TO WHICH THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE ?SUBSCRIPTION AGREEMENT?) REL |
|
| August 9, 2007 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2007; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Exact n |
|
| July 11, 2007 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2007 SPO MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 0-11772 25-1411971 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 14, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB MARK ONE x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended March 31, 2007; or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to COMMISSION FILE NUMBER: 0-11772 SPO MEDICA |
|
| May 11, 2007 |
424B3 1 v074298424b.htm FILED PURSUANT TO RULE 424(b)(3) REGISTRATION NO. 333-142141 PROSPECTUS SPO MEDICAL INC. 4,586,109 shares of Common Stock This Prospectus relates to the resale by the selling stockholders of up to 4,586,109 shares of our common stock, par value $0.001 (the "Common Stock") including 948,949 shares of Common Stock and up to 3,637,160 Common Shares issuable upon exercise of ou |
|
| April 16, 2007 | ||
| April 16, 2007 |
WARRANT FOR THE PURCHASE OF COMMON SHARES OF STOCK Exhibit 4.8 THIS WARRANT AND THE ORDINARY SHARES OF STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS OR SIMILAR APPLICABLE LAWS IN OTHER JURISDICTIONS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STA |
|
| April 16, 2007 |
WARRANT FOR THE PURCHASE OF COMMON SHARES OF STOCK No. March 27, 2007 50,000 Shares EX-4.11 14 v071495ex4-11.htm Exhibit 4.11 THIS WARRANT AND THE ORDINARY SHARES OF STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS OR SIMILAR APPLICABLE LAWS IN OTHER JURISDICTIONS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIE |
|
| April 16, 2007 |
WARRANT FOR THE PURCHASE OF COMMON SHARES OF STOCK EX-4.6 3 v071495ex4-6.htm Exhibit 4.6 THIS WARRANT AND THE ORDINARY SHARES OF STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS OR SIMILAR APPLICABLE LAWS IN OTHER JURISDICTIONS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES AC |
|
| April 16, 2007 |
WARRANT FOR THE PURCHASE OF COMMON SHARES OF STOCK No. April 26, 2006 15,000 Shares EX-4.9 6 v071495ex4-9.htm Exhibit 4.9 THIS WARRANT AND THE ORDINARY SHARES OF STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS OR SIMILAR APPLICABLE LAWS IN OTHER JURISDICTIONS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES AC |
|
| April 16, 2007 |
WARRANT FOR THE PURCHASE OF SHARES EX-4.5 2 v071495ex4-5.htm Exhibit 4.5 THIS WARRANT AND THE SHARES, AS HEREIN DEFINED, ISSUABLE UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE " ACT"), OR ANY U.S. STATE SECURITIES LAWS OR SIMILAR APPLICABLE LAWS IN OTHER JURISDICTIONS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE ACT AND APPLICA |
|
| April 16, 2007 |
EX-10.12 16 v071495ex10-12.htm Exhibit 10.12 SPO MEDICAL INC. 21860 Burbank Blvd., North Building, Suite 380, Woodland Hills, California 91367 Tel: 818-888-4380 Fax: 818-888-4385 March 27, 2006 By Fax Innopex Limited. 140 Cidermill Ave., Concord, Ont. Canada L4K 4T5 Dear Sir: RE: Line of Credit facility I wish to confirm that we have agreed to the following: 1. Innopex Limited (“Innopex”) will ext |
|
| April 16, 2007 |
As Filed With the Securities and Exchange Commission on April 16, 2007 Registration No. |
|
| April 16, 2007 |
WARRANT FOR THE PURCHASE OF COMMON SHARES OF STOCK No. September 2005 15,000 Shares EX-4.7 4 v071495ex4-7.htm Exhibit 4.7 THIS WARRANT AND THE ORDINARY SHARES OF STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES LAWS OR SIMILAR APPLICABLE LAWS IN OTHER JURISDICTIONS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES AC |
|
| March 20, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-KSB MARK ONE: x ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Fiscal Year ended December 31, 2006 o TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIESEXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 0-11772 SPO MEDICAL INC. (Exact name of Small Business Issuer as specifie |
|
| April 11, 2006 | ||
| July 26, 2001 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2001 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-11772 UNITED DIAGNOSTIC, INC. (Exact name |
|
| May 14, 2001 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-QSB (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2001 OR p TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-11772 UNITED DIAGNOSTIC, INC. |
